These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 19422787)

  • 1. Antigenicity and immunogenicity of SARS-CoV S protein receptor-binding domain stably expressed in CHO cells.
    Du L; Zhao G; Li L; He Y; Zhou Y; Zheng BJ; Jiang S
    Biochem Biophys Res Commun; 2009 Jul; 384(4):486-90. PubMed ID: 19422787
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A 219-mer CHO-expressing receptor-binding domain of SARS-CoV S protein induces potent immune responses and protective immunity.
    Du L; Zhao G; Chan CC; Li L; He Y; Zhou Y; Zheng BJ; Jiang S
    Viral Immunol; 2010 Apr; 23(2):211-9. PubMed ID: 20374001
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Receptor-binding domain of severe acute respiratory syndrome coronavirus spike protein contains multiple conformation-dependent epitopes that induce highly potent neutralizing antibodies.
    He Y; Lu H; Siddiqui P; Zhou Y; Jiang S
    J Immunol; 2005 Apr; 174(8):4908-15. PubMed ID: 15814718
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Receptor-binding domain of SARS-CoV spike protein induces long-term protective immunity in an animal model.
    Du L; Zhao G; He Y; Guo Y; Zheng BJ; Jiang S; Zhou Y
    Vaccine; 2007 Apr; 25(15):2832-8. PubMed ID: 17092615
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antigenic and immunogenic characterization of recombinant baculovirus-expressed severe acute respiratory syndrome coronavirus spike protein: implication for vaccine design.
    He Y; Li J; Heck S; Lustigman S; Jiang S
    J Virol; 2006 Jun; 80(12):5757-67. PubMed ID: 16731915
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cross-neutralization of human and palm civet severe acute respiratory syndrome coronaviruses by antibodies targeting the receptor-binding domain of spike protein.
    He Y; Li J; Li W; Lustigman S; Farzan M; Jiang S
    J Immunol; 2006 May; 176(10):6085-92. PubMed ID: 16670317
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification and characterization of novel neutralizing epitopes in the receptor-binding domain of SARS-CoV spike protein: revealing the critical antigenic determinants in inactivated SARS-CoV vaccine.
    He Y; Li J; Du L; Yan X; Hu G; Zhou Y; Jiang S
    Vaccine; 2006 Jun; 24(26):5498-508. PubMed ID: 16725238
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of a critical neutralization determinant of severe acute respiratory syndrome (SARS)-associated coronavirus: importance for designing SARS vaccines.
    He Y; Zhu Q; Liu S; Zhou Y; Yang B; Li J; Jiang S
    Virology; 2005 Mar; 334(1):74-82. PubMed ID: 15749124
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Yeast-expressed recombinant protein of the receptor-binding domain in SARS-CoV spike protein with deglycosylated forms as a SARS vaccine candidate.
    Chen WH; Du L; Chag SM; Ma C; Tricoche N; Tao X; Seid CA; Hudspeth EM; Lustigman S; Tseng CT; Bottazzi ME; Hotez PJ; Zhan B; Jiang S
    Hum Vaccin Immunother; 2014; 10(3):648-58. PubMed ID: 24355931
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intranasal vaccination of recombinant adeno-associated virus encoding receptor-binding domain of severe acute respiratory syndrome coronavirus (SARS-CoV) spike protein induces strong mucosal immune responses and provides long-term protection against SARS-CoV infection.
    Du L; Zhao G; Lin Y; Sui H; Chan C; Ma S; He Y; Jiang S; Wu C; Yuen KY; Jin DY; Zhou Y; Zheng BJ
    J Immunol; 2008 Jan; 180(2):948-56. PubMed ID: 18178835
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recombinant Receptor-Binding Domains of Multiple Middle East Respiratory Syndrome Coronaviruses (MERS-CoVs) Induce Cross-Neutralizing Antibodies against Divergent Human and Camel MERS-CoVs and Antibody Escape Mutants.
    Tai W; Wang Y; Fett CA; Zhao G; Li F; Perlman S; Jiang S; Zhou Y; Du L
    J Virol; 2017 Jan; 91(1):. PubMed ID: 27795425
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Priming with rAAV encoding RBD of SARS-CoV S protein and boosting with RBD-specific peptides for T cell epitopes elevated humoral and cellular immune responses against SARS-CoV infection.
    Du L; Zhao G; Lin Y; Chan C; He Y; Jiang S; Wu C; Jin DY; Yuen KY; Zhou Y; Zheng BJ
    Vaccine; 2008 Mar; 26(13):1644-51. PubMed ID: 18289745
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protocol for recombinant RBD-based SARS vaccines: protein preparation, animal vaccination and neutralization detection.
    Du L; Zhang X; Liu J; Jiang S
    J Vis Exp; 2011 May; (51):. PubMed ID: 21587153
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibody binding site mapping of SARS-CoV spike protein receptor-binding domain by a combination of yeast surface display and phage peptide library screening.
    Zhang X; Wang J; Wen K; Mou Z; Zou L; Che X; Ni B; Wu Y
    Viral Immunol; 2009 Dec; 22(6):407-15. PubMed ID: 19951177
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recombinant receptor-binding domain of SARS-CoV spike protein expressed in mammalian, insect and E. coli cells elicits potent neutralizing antibody and protective immunity.
    Du L; Zhao G; Chan CC; Sun S; Chen M; Liu Z; Guo H; He Y; Zhou Y; Zheng BJ; Jiang S
    Virology; 2009 Oct; 393(1):144-50. PubMed ID: 19683779
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction of specific immune responses by severe acute respiratory syndrome coronavirus spike DNA vaccine with or without interleukin-2 immunization using different vaccination routes in mice.
    Hu H; Lu X; Tao L; Bai B; Zhang Z; Chen Y; Zheng F; Chen J; Chen Z; Wang H
    Clin Vaccine Immunol; 2007 Jul; 14(7):894-901. PubMed ID: 17494640
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potent and persistent antibody responses against the receptor-binding domain of SARS-CoV spike protein in recovered patients.
    Cao Z; Liu L; Du L; Zhang C; Jiang S; Li T; He Y
    Virol J; 2010 Nov; 7():299. PubMed ID: 21047436
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development and characterization of a severe acute respiratory syndrome-associated coronavirus-neutralizing human monoclonal antibody that provides effective immunoprophylaxis in mice.
    Greenough TC; Babcock GJ; Roberts A; Hernandez HJ; Thomas WD; Coccia JA; Graziano RF; Srinivasan M; Lowy I; Finberg RW; Subbarao K; Vogel L; Somasundaran M; Luzuriaga K; Sullivan JL; Ambrosino DM
    J Infect Dis; 2005 Feb; 191(4):507-14. PubMed ID: 15655773
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neutralizing epitopes of the SARS-CoV S-protein cluster independent of repertoire, antigen structure or mAb technology.
    Berry JD; Hay K; Rini JM; Yu M; Wang L; Plummer FA; Corbett CR; Andonov A
    MAbs; 2010; 2(1):53-66. PubMed ID: 20168090
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SARS vaccine development.
    Jiang S; He Y; Liu S
    Emerg Infect Dis; 2005 Jul; 11(7):1016-20. PubMed ID: 16022774
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.